One of the major challenges with TKIs is the development of resistance. Cancer cells can acquire secondary mutations in the kinase domain, rendering TKIs ineffective. For example, the T315I mutation in the BCR-ABL gene can make CML resistant to imatinib. Research is ongoing to develop second- and third-generation TKIs to overcome such resistance.
